Abstract:Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to determine whether zidovudine-sparing first-line antiretroviral therapy would lead to less lipoatrophy and other metabolic changes than zidovudine-containing therapy. Methodology/principal findings: Fifty antiretroviral therapy-naïve HIV-1 infected men with an indication to start antiretroviral therapy were included in a randomized single blinded clinical trial. Randomisation was between zidovudine-containing therapy (zidovudine/lamivudine+lopinavir/ritonavir) and zidovudine-sparing therapy (nevirapine+lopinavir/ritonavir). Main outcome measures were body composition assessed by computed tomography and dual-energy X-ray absorptiometry scan and lipid profile before and after 3, 12, 24 months of antiretroviral therapy. In the zidovudine/lamivudine+lopinavir/ritonavir group, from 3 months onward limb fat decreased progressively by 684+/-293 grams (estimated mean+/-standard error of the mean)(p = 0.02) up to 24 months whereas abdominal fat increased, but exclusively in the visceral compartment (+21.9+/-8.1 cm(2), p = 0.008)). In contrast, in the nevirapine+lopinavir/ritonavir group, a generalized increase in fat mass was observed. After 24 months no significant differences in high density lipoprotein and total/high density lipoprotein cholesterol ratio were found between both treatment groups, but total and low density lipoprotein cholesterol levels were higher in the nevirapine+lopinavir/ritonavir group (6.1+/-0.2 versus 5.3+/-0.2 and 3.6+/-0.1 versus 2.8+/-0.1 mmol/l respectively, p<0.05). Virologic response and safety were comparable in both groups. Conclusions/significance: Zidovudine/lamivudine+lopinavir/ritonavir, but not nevirapine+lopinavir/ritonavir in antiretroviral therapy-naïve patients, is associated with lipoatrophy and greater relative intraabdominal lipohypertrophy, suggesting that zidovudine/lamivudine contributes to both these features of lipodystrophy. These findings support to no longer consider zidovudine/lamivudine as one of the preferred possible components of first-line antiretroviral therapy where alternative treatments are available. Trial registration: ClinicalTrials.gov NCT 00122226.

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss

Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy

Nucleoside Reverse Transcriptase Inhibitors Attenuate Angiogenesis And Lymphangiogenesis By Impairing Receptor Tyrosine Kinases Signaling In Endothelial Cells.

Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors

Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease

Uridine Abrogates the Adverse Effects of Antiretroviral Pyrimidine Analogues on Adipose Cell Functions

Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study

Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials

Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders

Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage

HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals

Comparison of Serum Lipid Profile in HIV Positive Patients on ART with ART Naïve Patients

[Assessment of Mitochondrial Toxicity Induced by Zidovudine and Adefovir Dipivoxil in Rats].

Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113)

Comparative Study on Safety and Efficacy of Zidovudine Versus Stavudine Containing Combination Antiretroviral Therapy

Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection

Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial

Plasma Mitochondrial DNA Levels As a Biomarker of Lipodystrophy among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).

Hiv Protease Inhibitors Disrupt Lipid Metabolism By Activating Endoplasmic Reticulum Stress And Inhibiting Autophagy Activity In Adipocytes